article thumbnail

Artificial pancreas will be piloted in 1,000 diabetics, says NHS CEO

pharmaphorum

NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot study of the technology, according to chief executive Sir Simon Stevens. Medtronic meanwhile has developed a closed-loop system – the MiniMed 640G – which was launched in the UK in 2015 for use alongside a CGM. Sir Simon Stevens.

Diabetes 131
article thumbnail

Opinion: Market share isn’t the only metric for biosimilars’ success

STAT

the first biosimilar was launched in September 2015. These 22 products compete in nine molecule classes across oncology, rheumatology, diabetes care, and now ophthalmology. In the U.S., As I write this, there are 38 FDA-approved biosimilars ; 22 of them are commercially available. According to the most recent “U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

China poised to lead the way with world’s first oral insulin for type 2 diabetes: GlobalData

Express Pharma

Hefei Tianhui Biotechnology (HTIT) has recently submitted a marketing authorisation application (MAA) in China for the world’s first oral insulin for type 2 diabetes (T2D). The number of diagnosed prevalent cases of type 2 diabetes in China is estimated to grow at a CAGR of 2.21 per cent from 57.4 million in 2022 to 63.3

article thumbnail

Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn deal

pharmaphorum

For a diabetes specialist like Lilly that is an enticing prospect, but Protomer is also planning applications of its platform in other therapeutic areas, for example by developing peptide or proteins that could be activated in the body by small molecule drugs. Alborz Mahdavi.

article thumbnail

Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2

pharmaphorum

Sosei Heptares’ longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established rivals from Novo Nordisk and Eli Lilly. The post Sosei nets $10m Pfizer milestone as diabetes/obesity drug starts phase 2 appeared first on.

article thumbnail

SAEM Clinical Images Series: Penile Lesion with a Poor Prognosis

ALiEM - Pharm Pearls

2015 Jul;66(1):133-46. Epub 2015 May 7. link] Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, Kamdar MM, Steele DJ, Thadhani RI. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. doi: 10.1053/j.ajkd.2015.01.034. 2015.01.034. PMID: 25960299; PMCID: PMC4696752.

Hospitals 152
article thumbnail

Living the life of a type 2 diabetes patient for a day

pharmaphorum

Mark Doyle, co-founder of The Method and creator of the A Life in a Day programme, tells us about the immersive experience he and his team created that allows anyone to live the life of a type 2 diabetes patient for 24 hours. Therefore, Doyle and his team created The Life in a Day immersive experience for type 2 diabetes.